The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Immune response to racotumomab in a child with relapsed neuroblastoma
|
|---|---|
| Published in |
Frontiers in oncology, January 2012
|
| DOI | 10.3389/fonc.2012.00195 |
| Pubmed ID | |
| Authors |
C. Sampor, M. D. Guthmann, A. Scursoni, W. Cacciavillano, A. Torbidoni, L. Galluzzo, S. Camarero, J. Lopez, M. T. G. de Dávila, L. Fainboim, G. L. Chantada |
| Abstract |
Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Czechia | 1 | 9% |
| Germany | 1 | 9% |
| Unknown | 9 | 82% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 1 | 9% |
| Student > Bachelor | 1 | 9% |
| Student > Master | 1 | 9% |
| Researcher | 1 | 9% |
| Professor > Associate Professor | 1 | 9% |
| Other | 1 | 9% |
| Unknown | 5 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 4 | 36% |
| Medicine and Dentistry | 2 | 18% |
| Unknown | 5 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2016.
All research outputs
#15,176,334
of 25,992,468 outputs
Outputs from Frontiers in oncology
#4,181
of 22,861 outputs
Outputs of similar age
#157,801
of 252,854 outputs
Outputs of similar age from Frontiers in oncology
#46
of 162 outputs
Altmetric has tracked 25,992,468 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,861 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 252,854 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 162 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.